Stratasys stock surged after the company reported fiscal third-quarter 2024 revenue of $140.01 million, down 13.6% year-on-year. read more ​ ​Stratasys stock surged after the company reported fiscal third-quarter 2024 revenue of $140.01 million, down 13.6% year-on-year. read moreÂ
Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position. read more ​ ​Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position. read moreÂ
Spire plans to use the sale proceeds to fully pay off its outstanding debt and invest in growth opportunities. read more ​ ​Spire plans to use the sale proceeds to fully pay off its outstanding debt and invest in growth opportunities. read moreÂ
This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.